Literature DB >> 19037717

Genome-wide reduction in transcriptomal profiles of varicella-zoster virus vaccine strains compared with parental Oka strain using long oligonucleotide microarrays.

Esther Grinfeld1, Alan Ross, Thorsten Forster, Peter Ghazal, Peter G E Kennedy.   

Abstract

Varicella-Zoster virus (VZV) causes varicella as a primary infection following which it becomes latent in human ganglia and then reactivates to cause herpes zoster. VZV vaccines are used to prevent primary infection with varicella, and also to reduce the incidence of viral reactivation causing herpes zoster and post-herpetic neuralgia. To gain further insights into the molecular basis of their attenuated virulence, we used long oligonucleotide microarrays to determine the lytic transcriptomal profiles of two vaccine VZV strains (Merck and GSK) compared with the Oka parental (P-Oka) strain. There was a global downregulation of transcription of both vaccines relative to P-Oka, although this downregulation was more extensive in the GSK strain. Open Reading Frames (ORFs) 62 and 14 were the most transcriptionally downregulated on the arrays for both vaccines compared with the parental strain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19037717     DOI: 10.1007/s11262-008-0304-3

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  18 in total

1.  Varicella-zoster virus gene expression in latently infected and explanted human ganglia.

Authors:  P G Kennedy; E Grinfeld; J E Bell
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 2.  Experiments using microarray technology: limitations and standard operating procedures.

Authors:  T Forster; D Roy; P Ghazal
Journal:  J Endocrinol       Date:  2003-08       Impact factor: 4.286

3.  Comparative analyses of the 9 glycoprotein genes found in wild-type and vaccine strains of varicella-zoster virus.

Authors:  Johnathan Storlie; Lucie Maresova; Wallen Jackson; Charles Grose
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

4.  Transcriptomal analysis of varicella-zoster virus infection using long oligonucleotide-based microarrays.

Authors:  Peter G E Kennedy; Esther Grinfeld; Marie Craigon; Klemens Vierlinger; Douglas Roy; Thorsten Forster; Peter Ghazal
Journal:  J Gen Virol       Date:  2005-10       Impact factor: 3.891

5.  Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity.

Authors:  Y Gomi; T Imagawa; M Takahashi; K Yamanishi
Journal:  J Med Virol       Date:  2000-08       Impact factor: 2.327

6.  Latent varicella-zoster virus is located predominantly in neurons in human trigeminal ganglia.

Authors:  P G Kennedy; E Grinfeld; J W Gow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

Review 7.  Varicella zoster virus latency, neurological disease and experimental models: an update.

Authors:  Randall J Cohrs; Donald H Gilden; Ravi Mahalingam
Journal:  Front Biosci       Date:  2004-01-01

Review 8.  Varicella vaccine: the American experience.

Authors:  A A Gershon; P LaRussa; I Hardy; S Steinberg; S Silverstein
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

9.  Comparison of virus transcription during lytic infection of the Oka parental and vaccine strains of Varicella-Zoster virus.

Authors:  Randall J Cohrs; Donald H Gilden; Yasuyuki Gomi; Koichi Yamanishi; Jeffrey I Cohen
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

10.  Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse.

Authors:  J F Moffat; L Zerboni; P R Kinchington; C Grose; H Kaneshima; A M Arvin
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

View more
  6 in total

1.  A varicella-zoster virus mutant impaired for latency in rodents, but not impaired for replication in cell culture.

Authors:  Aruna P N Ambagala; Tammy Krogmann; Jing Qin; Lesley Pesnicak; Jeffrey I Cohen
Journal:  Virology       Date:  2010-02-08       Impact factor: 3.616

2.  Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques.

Authors:  V Traina-Dorge; B Pahar; P Marx; P Kissinger; D Montefiori; Y Ou; W L Gray
Journal:  Vaccine       Date:  2010-07-21       Impact factor: 3.641

Review 3.  Varicella-zoster.

Authors:  Don Gilden; Maria A Nagel; Randall J Cohrs
Journal:  Handb Clin Neurol       Date:  2014

4.  Assessment of transcriptomal analysis of Varicella-Zoster-virus gene expression in patients with and without post-herpetic neuralgia.

Authors:  G H Ashrafi; Esther Grinfeld; Paul Montague; Thorsten Forster; Alan Ross; Peter Ghazal; Fiona Scott; Judith Breuer; Roslyn Goodwin; Peter G E Kennedy
Journal:  Virus Genes       Date:  2010-07-23       Impact factor: 2.198

5.  Long-read sequencing uncovers a complex transcriptome topology in varicella zoster virus.

Authors:  István Prazsák; Norbert Moldován; Zsolt Balázs; Dóra Tombácz; Klára Megyeri; Attila Szűcs; Zsolt Csabai; Zsolt Boldogkői
Journal:  BMC Genomics       Date:  2018-12-04       Impact factor: 3.969

6.  Deep Sequencing of Distinct Preparations of the Live Attenuated Varicella-Zoster Virus Vaccine Reveals a Conserved Core of Attenuating Single-Nucleotide Polymorphisms.

Authors:  Daniel P Depledge; Koichi Yamanishi; Yasuyuki Gomi; Anne A Gershon; Judith Breuer
Journal:  J Virol       Date:  2016-09-12       Impact factor: 6.549

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.